Varex Imaging Stockholders Approve Teledyne Merger at Special Meeting; Deal on Track to Close

The Quick Take

• Varex Imaging stockholders voted to approve the merger agreement with Teledyne Technologies at a special meeting held October 28, 2026.
• Out of 42,463,446 shares of common stock outstanding, the vast majority voted in favour of the Teledyne acquisition.
• The merger was originally announced on August 10, 2026, involving Teledyne subsidiary Detect Merger Sub Inc completing the acquisition.
• Stockholder approval removes a major contingency, placing the deal on track for regulatory close expected in coming weeks.
• Teledyne's acquisition strengthens its position in the X-ray imaging components market used in medical, security, and industrial applications.

Varex Imaging's stockholder vote in favour of the Teledyne Technologies acquisition represents a significant milestone in the M&A process, effectively eliminating the shareholder approval risk that had been the most immediate contingency standing between announcement and closing. With the stockholder vote clearing by a substantial margin — out of over 42 million outstanding shares — the deal now primarily awaits regulatory clearance from antitrust authorities, which is typically the final hurdle in technology hardware sector mergers of this type. Teledyne has demonstrated a consistent track record of successfully navigating regulatory reviews in previous acquisitions.

The strategic rationale for Teledyne's acquisition of Varex is straightforward and financially compelling. Varex is the world's leading supplier of X-ray imaging components, including digital detectors and X-ray tubes used in medical diagnostics, airport and cargo security screening, and industrial inspection systems. These markets share characteristics that align well with Teledyne's existing business model: high technical barriers to entry, long customer relationships, recurring replacement cycles, and opportunities for software and data analytics value-add. The acquisition extends Teledyne's sensing and imaging capabilities into a complementary technology.

For Varex shareholders, the acquisition represents a premium exit from a business navigating a challenging period characterised by post-pandemic demand normalisation in medical imaging equipment and capital expenditure caution among hospital systems. The certainty of a cash acquisition at a premium to the pre-announcement trading price offers a more attractive risk-adjusted outcome than remaining an independent company in a market requiring significant continued investment in detector and tube technology to maintain the competitive advantages that made Varex attractive to a strategic buyer like Teledyne in the first place.

Synthesized from 2 sources.